NCT01732588View on ClinicalTrials.gov

A Comparison of the Bioavailability of OZ439 When Delivered Directly to the Small Intestine, or Via the Oral Route

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

December 31, 2012

Study Completion Date

December 31, 2012

Conditions

Healthy Volunteers

Interventions

DRUG

OZ439 120mg PIB

120mg dose (as free base) of OZ439 as a solution made up from powder in bottle (PIB)

DRUG

120 mg OZ439 caplet

120 mg (as free base) of OZ439 immediate-release (IR) caplet formulation containing nanoparticulate, administered directly via the oral route

DRUG

120mg OZ439 caplet via Enterion capsule

120 mg OZ439 (as free base) in an immediate release (IR) caplet formulation containing nanoparticulate,administered orally via the Enterion capsule and delivered directly to the proximal small bowel (PSB)

Trial Locations (1)

NG11 6JS

Quotient Clinical, Nottingham

All Listed Sponsors

lead

Medicines for Malaria Venture

OTHER

NCT01732588 - A Comparison of the Bioavailability of OZ439 When Delivered Directly to the Small Intestine, or Via the Oral Route | Biotech Hunter | Biotech Hunter